JUNO THERAPEUTICS INC's ticker is JUNO and the CUSIP is 48205A109. A total of 176 filers reported holding JUNO THERAPEUTICS INC in Q3 2016. The put-call ratio across all filers is 0.85 and the average weighting 1.0%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2017 | $10,513,000 | +4.2% | 230,000 | +2.2% | 0.48% | +2.4% |
| Q3 2017 | $10,094,000 | +50.1% | 225,000 | 0.0% | 0.47% | +37.1% |
| Q2 2017 | $6,725,000 | +53.9% | 225,000 | +14.2% | 0.34% | +34.9% |
| Q1 2017 | $4,371,000 | +17.7% | 197,001 | 0.0% | 0.25% | +1.6% |
| Q4 2016 | $3,713,000 | -37.2% | 197,001 | 0.0% | 0.25% | -33.2% |
| Q3 2016 | $5,912,000 | -21.9% | 197,001 | 0.0% | 0.37% | -33.9% |
| Q2 2016 | $7,573,000 | +0.9% | 197,001 | 0.0% | 0.56% | -10.8% |
| Q1 2016 | $7,504,000 | -13.4% | 197,001 | 0.0% | 0.63% | -4.1% |
| Q4 2015 | $8,662,000 | +8.1% | 197,001 | 0.0% | 0.66% | +0.8% |
| Q3 2015 | $8,016,000 | -23.7% | 197,001 | +0.0% | 0.65% | -15.1% |
| Q2 2015 | $10,506,000 | +41.5% | 197,000 | +60.9% | 0.77% | +10.4% |
| Q1 2015 | $7,426,000 | -1.5% | 122,426 | -15.2% | 0.70% | -21.2% |
| Q4 2014 | $7,542,000 | – | 144,426 | – | 0.88% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Crestline Management, LP | 25,948,799 | $1,132,937,000 | 100.00% |
| Biomark Capital Management Co. LLC | 1,602,562 | $70,465,000 | 85.76% |
| Omega Fund Management, LLC | 1,229,512 | $54,062,000 | 30.09% |
| Clarius Group, LLC | 218,942 | $9,626,000 | 2.93% |
| BB BIOTECH AG | 1,305,000 | $57,381,000 | 1.62% |
| Casdin Capital, LLC | 17,500 | $769,000 | 0.68% |
| Rock Springs Capital Management LP | 197,001 | $8,662,000 | 0.66% |
| BENNETT LAWRENCE MANAGEMENT L L C/NY | 38,850 | $1,708,000 | 0.55% |
| ArrowMark Colorado Holdings LLC | 383,749 | $16,873,000 | 0.46% |
| SUFFOLK CAPITAL MANAGEMENT LLC | 68,848 | $3,027,000 | 0.38% |